|
Dan Von Hoff is currently Senior Investigator and Head of Translational Research at the Translational Genomics Research Institute (TGEN) in Phoenix, Arizona. Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. In the area of clinical drug development, Dr. Von Hoff and his colleagues were involved in the early development of many of the agents we now use routinely, including: Mitoxantrone, Findarabine, Paclitaxel, Docetaxel, Gemcitabine, CPT-11, Iressa, Tarceva and others. He has worked with ~300 cancer agents in clinical trials and is associated with ~30 approved NDAs. Dr. Von Hoff is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology . He is a founder and board member of ILEX Oncology, Inc. (ILXO, NASDAQ). He also serves as chief scientific officer for U.S. Oncology (NASDAQ: USON). He is founder and the Editor Emeritus of Investigational New Drugs - The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics and has published more than 480 papers, 125 book chapters, and 820 abstracts. | 